• Policy
• "Seek social consensus, shift away from 2,000 quota"
• by Lee, Jeong-Hwan Mar 29, 2024 05:53am

• Company
• AZ’s Sidapvia can be prescribed in general hospitals in KOR
• by Eo, Yun-Ho Mar 29, 2024 05:53am

• Company
• Reimb of renal anemia drug in progress upon FDA approval
• by Nho, Byung Chul Mar 29, 2024 05:53am

• Policy
• NHIS expands info disclosure about drug pricing negotiations
• by Lee, Tak-Sun Mar 29, 2024 05:53am

• Policy
• JW Pharmaceutical agrees on RSA renewal terms for Hemlibra
• by Lee, Tak-Sun Mar 29, 2024 05:53am

• Company
• Samsung Bioepis makes 3rd investment in ADCs
• by Son, Hyung-Min Mar 28, 2024 05:52am

• Company
• HK Inno.N speeds up clinical research on its NSCLC candidate
• by Nho, Byung Chul Mar 28, 2024 05:52am

• Company
• New breast cancer drug ‘Truqap’ soon to land in KOR
• by Eo, Yun-Ho Mar 28, 2024 05:52am

• Company
• AI-based liquid biopsy companies deliver tangible results
• by Son, Hyung-Min Mar 28, 2024 05:52am

• Policy
• LG Chem expands its Zemimet SR Tab lineup
• by Lee, Tak-Sun Mar 28, 2024 05:52am